CDC Newsroom

CDC study shows effectiveness of RSV immunization for infants

New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).

Read the original news at Centers for Disease Control and Prevention (CDC)

Related Articles

Back to top button